Patents by Inventor Andrew B. Nixon

Andrew B. Nixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
    Patent number: 10613091
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 7, 2020
    Assignee: Duke University
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
  • METHODS OF DEVELOPING A PROGNOSIS FOR PANCREATIC CANCER AND PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS
    Publication number: 20180156804
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Application
    Filed: January 11, 2018
    Publication date: June 7, 2018
    Applicant: DUKE UNIVERSITY
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
  • Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
    Patent number: 9869677
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: January 16, 2018
    Assignee: Duke University
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
  • METHODS OF DEVELOPING A PROGNOSIS FOR PANCREATIC CANCER AND PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS
    Publication number: 20160146822
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Application
    Filed: January 20, 2016
    Publication date: May 26, 2016
    Applicant: DUKE UNIVERSITY
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
  • Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
    Patent number: 9255927
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: February 9, 2016
    Assignee: DUKE UNIVERSITY
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
  • METHODS OF PREDICTING RESPONSIVENESS OF A CANCER TO AN AGENT AND METHODS OF DETERMINING A PROGNOSIS FOR A CANCER PATIENT
    Publication number: 20160024585
    Abstract: The present disclosure provides biomarkers, and methods of using such biomarkers, that are predictive for efficacy of and resistance to an EGFR targeting agent, such as cetuximab, or prognostic with respect to cancer survival.
    Type: Application
    Filed: May 4, 2015
    Publication date: January 28, 2016
    Applicant: DUKE UNIVERSITY
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Stephanie Mackey Cushman, Chen Jiang, Ivo Shterev, Kouros Owzar, Ace J. Hatch, Alexander B. Sibley
  • METHODS OF DEVELOPING A PROGNOSIS FOR PANCREATIC CANCER AND PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS
    Publication number: 20140127193
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Application
    Filed: May 7, 2012
    Publication date: May 8, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr